Carna Biosciences Inc
TSE:4572
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
JP |
Carna Biosciences Inc
TSE:4572
|
7.6B JPY | -2.8 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.8B USD | 35.4 | ||
US |
Danaher Corp
NYSE:DHR
|
184.8B USD | 34.9 | ||
US |
Agilent Technologies Inc
NYSE:A
|
41.8B USD | 25.9 | ||
CH |
Lonza Group AG
SIX:LONN
|
38B CHF | -132.3 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
56.3T KRW | 99 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.4B USD | 35.2 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | 33.5 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.8B USD | 68 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.8B USD | 24.6 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
18.8B EUR | 125.2 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.